RAPIDATA AND OTHER THINGS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 国际上最广泛认可的大分子晶体学方法课程之一在国家同步加速器光源（NSLS）举行。自1999年以来，来自世界各地的学生每年春天都会聚集在NSLS参加RapiData，这是一个为期一周的速成班，由Sweet，Alex Soares和Sal Sclafani组织，是P41项目的培训部分。它的目的是向参与者介绍最好的和最新的设备和技术的大分子x射线晶体学。RapiData允许学生与晶体学领域的领先软件开发人员会面并学习，然后实际使用NSLS光束线收集数据。今年，52名学生参加了4月11日至16日举行的讲习班。 自创建以来，已有近600名学生参加了这门课程，我们不断要求增加更多的插槽。许多RapiData校友现在已经成长为晶体学专家，他们继续将经验不足的同事推荐给BNL，以了解这个高度专业化领域的初始步骤。我们经常让前RapiData学生的研究生。 该课程开始于Sweet教授的为期一天的背景课程，旨在为经验不足的学生更新晶体学基础知识。接下来的两天充满了来自BNL，工业界，学术界和其他国家实验室的科学家的讲座和辅导。接下来，学生们被分成几组，并在八条NSLS光束线上进行了一场马拉松、60小时的数据收集会议。与此同时，许多教程正在进行中，由讲师自己运行。近三分之二的学生带来了自己的标本，目的是解决特定酶的结构，而其他人则观察和帮助。在这个过程中，大约有六个结构被解决了，每个结构都可能是一个可验证的结果。在课程的数据收集部分，学生们每天下午聚集在一起讨论他们的结果，并制作关于他们的数据和科学主题的迷你讲座。 看到学生们在一周内的技能发展总是令人兴奋的。他们中的许多人来这里时几乎没有晶体学经验，他们离开时知道如何获得和处理真实的数据，以及如何在出现问题时定位和解决问题。这就是有这样一个动手程序的好处。 除了能源部和国家卫生研究院的资助外，国际晶体学联合会还提供了一笔特别赠款，帮助七名拉丁美洲学生参加该课程。布鲁克海文科学协会、NSLS和几家设备供应商和制药公司提供了额外的支持。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. One of the most widely recognized courses internationally in macromolecular crystallography methods is held at the National Synchrotron Light Source (NSLS). Since 1999, students from around the world have gathered at the NSLS every spring for RapiData, a weeklong crash course organized by Sweet, Alex Soares, and Sal Sclafani, a training component of this P41 project. It's designed to introduce participants to the best and latest equipment and techniques for macromolecular x-ray crystallography. RapiData allows students to meet and learn from the leading developers of software in the crystallography field, and then to actually use NSLS beamlines to collect data. This year, 52 students attended the workshop, which was held from April 11-16. Since its creation, nearly 600 students have attended this course, and we have constant requests to add more slots. Many RapiData alumni have now blossomed into crystallography experts, and they continue to refer their less-experienced colleagues to BNL to learn the initial steps of this highly specialized area of interest. We regularly get graduate students of former RapiData students. The course began with a daylong background session taught by Sweet, meant to refresh the knowledge of crystallography fundamentals for less-experienced students. The following two days were filled with lectures and tutorials taught by scientists from BNL, industry, academia, and other national labs. Next, the students were divided into groups and guided through a marathon, 60-hour data-collection session on eight NSLS beamlines. At the same time, many tutorials were underway, run by the lecturers themselves. Nearly two-thirds of the students brought their own specimens with the goal of solving the structure of a particular enzyme, while the others observed and helped. About half a dozen structures were solved during the course, each of which could be a publishable result. During the data-collection portion of the course, the students gathered each afternoon to discuss their results and produced mini lectures about their data and scientific subject. It's always really exciting to watch the students' skills develop throughout the week. Many of them come here with little or no experience in crystallography, and they leave knowing how to obtain and process real data, as well as how to locate and fix problems as they arise. That's the advantage of having such a hands-on program. In addition to the DOE and NIH funding, a special grant was provided by the International Union for Crystallography to assist seven Latin American students in attending the course. Additional support was provided by Brookhaven Science Associates, the NSLS, and several equipment vendors and drug companies.